ReviewDisease models & mechanisms2011
C. elegans: model host and tool for antimicrobial drug discovery.
Review in Disease models & mechanisms, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- GK-11: a Novel Cationic Peptide with Antibiofilm Activity against Staphylococcus aureus and Pseudomonas aeruginosa.Probiotics and antimicrobial proteins · 2026Article
- Overcoming Polymyxin Resistance inACS omega · 2025Article
- SARS-CoV-2 Entry Can Be Mimicked inViruses · 2025Article
- In Vivo Efficacy of a Nanoconjugated Glycopeptide Antibiotic in Silkworm Larvae Infected byInsects · 2024Article
- Synergistic antimicrobial combination of third-generation cephalosporins and polymyxin B against carbapenem-polymyxin-resistantAntimicrobial agents and chemotherapy · 2024Article
- Beneficial Effects ofAntioxidants (Basel, Switzerland) · 2024Article
- Immunity-linked genes are stimulated by a membrane stress pathway linked to Golgi function and the ARF-1 GTPase.Science advances · 2023Article
- In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms · 2023Article
- High-throughput small molecule screen identifies inhibitors of microsporidia invasion and proliferation in C. elegans.Nature communications · 2022Article
- Bacteriophage Therapy forFrontiers in cellular and infection microbiology · 2022Review
- Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms ComprisingFrontiers in cellular and infection microbiology · 2022Article
- Evaluation ofFrontiers in pharmacology · 2022Article
- A nematode-derived, mitochondrial stress signaling-regulated peptide exhibits broad antibacterial activity.Biology open · 2021Article
- Ubiquitin-related processes and innate immunity in C. elegans.Cellular and molecular life sciences : CMLS · 2021Review
- Article
- Comprehensive genetic analysis of adhesin proteins and their role in virulence of Candida albicans.Genetics · 2021Article
- Identification of a Novel Cathelicidin from theToxins · 2020Article
- Healthspan pathway maps inAging · 2020Review
- Animal Models to Translate Phage Therapy to Human Medicine.International journal of molecular sciences · 2020Review
- Caenorhabditis elegans as a model animal for investigating fungal pathogenesis.Medical microbiology and immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For almost four decades, the nematode Caenorhabditis elegans has been of great value in many fields of biological research. It is now used extensively in studies of microbial pathogenesis and innate immunity. The worm lacks an adaptive immune system and relies solely on its innate immune defences to cope with pathogen attack. Infectious microbes, many of which are of clinical interest, trigger specific mechanisms of innate immunity, and provoke the expression of antifungal or antibacterial polypeptides. In this review, we highlight some of these families of antimicrobial peptides (AMPs) and proteins that are candidates for the development of novel antibiotics. In addition, we describe how systems of C. elegans infection provide an increasing number of possibilities for large-scale in vivo screens for the discovery of new antimicrobial drugs. These systems open promising perspectives for innovative human therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.